p300/CBP Methylation is Involved in the Potential Carcinogenic Mechanism of Lung Cancer by Zhang, Yu et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







p300/CBP Methylation is Involved 
in the Potential Carcinogenic 
Mechanism of Lung Cancer
Yu Zhang, Wei Shen, Jin Zou and Shibo Ying
Abstract
p300/CBP is involved in the expression of a wide range of genes, both as a histone 
acetyltransferase (HAT) and as a coactivator of transcription factors. p300/CBP is 
the specific substrate of CARM1, and its KIX domain and GBD domain are the main 
sites methylated by arginine methyltransferase 4 (PRMT4/CARM1). p300/CBP plays 
an important role in lung cancer, which is a cell cycle disease. More importantly, the 
methylation of p300/CBP by CARM1 affects the progression of lung cancer through 
the cAMP-PKA pathway, p53 pathway and ER pathway. The structure, function, 
methylation modification sites, methylation-related enzymes, genes associated with 
lung cancer and the possible mechanisms of p300/CBP action are reviewed.
Keywords: p300/CBP, methylation, CARM1, signal transduction pathway, EMT,  
lung cancer
1. Introduction to the p300/CBP protein
1.1 Structure and function of p300/CBP
The p300/CBP molecule has at least eight functional domains. The nuclear 
receptor scope (RID) mainly interacts with the nuclear receptor and has a cysteine-
histidine-rich domain (a CH domain), namely, the CH1 domain, also known 
as transcription articulation zinc finger domain 1 (TAZ1). The CH2 domain in 
RID includes the RING and PHD domains. The RING domain is an E3 ligase that 
mediates the transfer of ubiquitin to substrates by binding an E2 ubiquitin binding 
enzyme [1]. The PHD domain is a zinc finger domain that identifies the methylated 
state of histones. The CH3 domain includes ZZ ZZ-type zinc finger domain (ZZ) 
and transcription cohesive device zinc finger domain 2 (TAZ2). The HAT domain 
of p300/CBP is the structural basis of the transcription complex bridge formed 
by multiple transcription factors and functions as an acetylase. The structural 
failure of RING-HAT connections or RING domain, and particularly the loss of 
the RING domain, usually results in significant increases in the automatic acetyla-
tion of p300/CBP and in the acetylation of p53 [2]. The bromine domain binds 
to acetylated histones and transcription factors in nucleosomes. The deletion or 
mutation of the bromine domain does not eliminate HAT domain activity but 
interferes with substrate targeting and transcriptional activity [3], and bromine 
domain inhibitors have been shown to reduce the expression of G protein signal 
regulators (RGS4) [4]. The KIX domain is a CREB-binding site and the main motif 
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modified by CARM1 methylation. Steroidal hormone receptor coactivator 1 (SID) 
mainly mediates protein-protein interactions, and many cell and viral proteins bind 
to this region, which is also the domain of the srC-1 interaction [5]. In glutamine- 
and proline-rich domains in the N-terminus and C-terminus have transactivation 
domains (TA domains), and their main function is activating transcription.
1.2 Major methylation sites of p300/CBP and related enzymes
As early as 2005, it was reported that three arginine methylation sites were found 
in the GBD domain (GRIP1-binding domain) in the C-terminus of p300, Arg-2056; 
Arg-2088; and Arg-2142. Among these residues, Arg-2142 is the most important 
site, and the methylation of Arg-2142 strongly inhibits the interaction between 
p300 and GRIP1 [6]. In subsequent studies, the importance of Arg-754 methyla-
tion in the p300·KIX domain in the cell response to DNA damage was gradually 
discovered, and Arg-754 in CBP is analogous to one of the three arginine residues in 
p300 mentioned above. The KIX domain of p300/CBP is not only the binding site of 
CREB but also the main site of CARM1 methylation modification, and studies have 
confirmed that CARM1 can be methylated to modify p300/CBP molecules both in 
vivo and in vitro, with Arg-754 being the main site for CARM1 methylation. It has 
been found that the methylation of Arg-754 can recruit the p53-binding region of 
BRCA1 to the p21 promoter, initiating the activation of p53 and, subsequently, p21 
in response to DNA damage [7].
It has also been reported that the methylation site of CBP·KIX, Arg-580, is highly 
methylated by CARM1 in vitro, and Arg-600 of the CBP·KIX domain (equivalent to 
Arg-580 of p300·KIX) is located on the outer surface of the KIX-KID complex. Its 
methylation blocks the activation of CREB by blocking the interaction between KIX 
and the CREB kinase-induced domain (KID)[8]. In addition, CBP protein residues 
Arg714, Arg742 and Arg768 are the main methylation sites of CARM1 in vitro, and 
R742 is the main methylation site of CARM1 in vivo [9].
2. Expression of p300/CBP and CARM1 in lung cancer
2.1 The role of high p300/CBP expression in lung cancer tissues
Highly expressed p300 significantly enhances the ability of cancer cells to invade 
and migrate in non-small cell lung cancer (NSCLC). If the p300 gene is knocked 
out, the invasion and invasion ability of the cancer cells is significantly reduced, 
which may be related to the increased ZEB1 activity caused by the formation of 
the p300-Smad complex and further induction of the EMT [10]. CBP is highly 
expressed in lung cancer cells and tumor tissues. CBP acetylation is associated with 
cleavage and polyadenylation specificity factor subunit 4 (CPSF4) in the gene pro-
moter region and synergically regulates downstream gene transcription and tumor 
cell proliferation. This association between CBP and the CPSF4 and its synergistic 
effect on the activation of human telomerase reverse transcriptase (hTERT) expres-
sion may contribute to the involvement of CBP in the mechanism promoting lung 
cancer growth [11, 12].
2.2 CARM1 is highly expressed in lung cancer tissues
Silencing CARM1 expression significantly reduced the apoptosis rate of lung 
cancer cells and significantly promoted the migration of lung cancer cells, while the 
overexpression of CARM1 significantly increased the apoptosis rate of lung cancer 
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cells and reduced the migration of lung cancer cells, suggesting that CARM1 may 
attenuate the development of lung cancer [13]. Notably, a recent study found that 
the overexpression of CARM1 leads to methylated H3R17me2a and H3R26me2a at 
the core promoter region of the gene encoding the cell cycle protein E2 (CCNE2), 
activating CCNE2 expression at the height of the cell cycle, which facilitated the 
G1/S phase transition and promoted cell proliferation and colony formation. The 
overexpression of CCNE2 is often observed in lung cancer tissues, and the tumor-
promoting effect of CARM1 in NSCLC has been shown by in vitro experiments [14].
Since CARM1 and PRMT1 are highly expressed in lung cancer tissues and 
expressed at low levels in normal tissues, CARM1 distribution was significant. 
Increased keratin expression and neurometalloprotein B receptor (NMBR) expres-
sion were observed in CARM1-knockout cancer cells, demonstrating that CARM1 
expression is associated with lung cancer differentiation and staging [15].
3. Carcinogenic mechanism involves p300/CBP methylation
3.1 p53 pathway and p21WAF1/CIP1 activation mechanism
p21 is a member of the KIP/CIP family of cyclin-dependent kinase (Cdk) 
inhibitors (CKIs) and inhibits the action of all Cdk complexes throughout the cell 
cycle by occupying the ATP-binding site of the Cdk complex; therefore, it is also 
known as cyclin inhibitory protein 1 (p21WAF1/CIP1).
When DNA is damaged, the expression of the p53 gene is induced, and then, p53 
induces p21WAF1/CIP1 expression. The methylation of Arg-754 in the P300·KIX domain 
is essential for p53 activation of p21WAF1/CIP1. First, p53 recruits CARM1-methylated 
p300 before it recruits BRCA1 and then mediates the interaction between the p21 
promoter and the p53-binding region to initiate the activation of p53 and of p21 [7]. 
Activated P21WAF1/CIP1, cyclin, Cdk and proliferating cell nuclear antigen (PCNA) 
combine to form the cyclin-Cdk-p21-PCNA tetramer complex, which prevents the 
cell proliferation signal from effectively being transmitted, and the damaged cell is 
arrested in the G1 phase, inducing transcription of the DNA repair gene GADD45. If 
a damaged cell remains stagnated in the G1 phase, p53 is induced to activate the apop-
totic gene Bax and thus initiate cell apoptosis (Figure 1a). It has also been reported 
that the expression of p21WAF1/CIP1 was directly upregulated p300/CBP-induced 
acetylation of KLF6 [16]. Peroxisomal proliferative factor receptor γ (PPAR-γ) also 
directly upregulated p21WAF1/CIP1 expression in lung cancer cells.
3.2 cAMP-PKA pathways
As one of the most common signaling pathways of G protein-coupled recep-
tors, the cAMP-PKA pathway plays a very important role in the regulation of cell 
activity. Many signaling molecules, such as glucagon, adrenaline and corticotropin, 
are regulated by this pathway. Under normal physiological conditions, adenylate 
cyclase (AC) is activated after the ligand binds specifically to the receptor, and AC 
converts intracellular ATP into cAMP, which is an intracellular second messenger. 
cAMP activates cAMP-dependent protein kinase A (PKA), and the free C-subunit 
of PKA encounters a specific serine residue (Ser133) site in the kinase-induced 
domain of cAMP reactive element-binding protein (CREB) which is phosphorylated 
within the nucleus to recruit p300/CBP molecules [17]. Through p300/CBP acetyla-
tion, which promotes general transcription factors (such as TFIIB) binding with 
the target gene promoter, target gene expression is regulated. Activated CREB has a 
wide range of cytological effects, including in vitro participation in the regulation of 
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cell migration/invasion, cell proliferation, cell survival, Warburg effect induction, 
etc. It is involved in the immune response, tumorigenicity, vascular growth and 
tumor progression in vivo [18]. However, p300/CBP·KIX was modified by CARM1 
methylation, which blocked the activation of CREB and induced apoptosis by 
preventing the combination of KIX and KID [8] (Figure 1b).
In addition, LKB1 is the target of mutational inactivation in sporadic cancers, 
especially NSCLC. LKB1 is mutated in approximately 20%-30% of NSCLC cases, 
making it the third most common genetic change site after P53 and K-RAS. The 
inactivation of LKB1 and subsequent activation of cyclic adenosine reactive 
element-binding protein (CREB)/CREB regulating transcription coactivator 
(CRTC) induced LINC00473. LINC00473 is a nuclear gene that interacts with 
NONO, which is a component of the cyclic adenosine signaling pathway, to pro-
mote CRTC/CREB-mediated transcription. LINC00473 is critical for maintaining 
the growth and survival of lung cancer cells [19]. Methylation of the p300/CBP·KIX 
domain blocks the activation of CREB and may also affect the expression of CRTC-
mediated LINC00473, thereby blocking the progression of lung cancer.
3.3 The estrogen receptor (ER) pathway
Many steroid hormone receptors are expressed on the surface of lung cancer 
cells, including estrogen receptor (ER). When ligands (such as estrogen) diffuse 
into cells or undergo in situ synthesis and when ERs are induced to form homolo-
gous or heterologous dimers, these dimers combine with nuclear DNA enhancer 
ERE estrogen response elements (EHRs) and recruit steroid receptor auxiliary 
activation factor-3 (SRC-3). The study found that the ER compound needs two 
SRC-3 to form an initial stable ERE/ERα/SRC-3a/SRC-3b/p300 core complex. This 
is a key step in establishing the core ER coactivator complex and recruiting the p300 
protein to the ER genomic binding site [20].
Figure 1. 
a: p300/CBP methylation by CARM1 blocks the ER pathway by inhibiting the formation of core transcription 
complexes; b: P300/CBP methylation by CARM1 blocks cAMP-PKA-CREB activation; c: P300/CBP 
methylation by CARM1 is beneficial to p53-dependent p21 activation. ┫ (red): inhibition; → (green): 
promotion. AC: adenylate cyclase; ATP: Adenosine triphosphate; cAMP: adenosine cyclophosphate; PKA: 
protein kinase A; SRC-3: steroid receptor coactivator-3; ER: estrogen receptor; Cdk: cyclin-dependent kinases; 
PCNA: proliferating cell nuclear antigen; CREB: cAMP-response element binding protein; CRE: cAMP 
response element; P: phosphorylation; Me: Methylation.
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In subsequent studies, sequential recruitment and transcriptional activation 
models of the coactivators of ER were proposed: each ER monomer recruits one 
SRC-3, two SRC-3 molecules work together to lock one p300 molecule safely 
into the ER complex, and then, histone H3 acetylation is initiated. Next, CARM1 
binds to the complex, where it can easily methylate its substrates SRC-3, p300, 
and histones. Due to the proximity of SRC-3b to ER, SRC-3a and p300, the bind-
ing of CARM1 to the ER complex results in the release of SRC-3b, and CARM1 
occupies the site vacated by SRC-3b. Second, the combination with CARM1 leads 
to further conformational changes of p300. This structural change caused by 
the sequential coactivator recruitment process further alters the activity of p300 
acetyltransferase and the activity of CARM1 HMT on histone H3. The synergis-
tic effect of CARM1 and p300 enhances the acetylation of histone H3K18 and 
the methylation of H3R17 and promotes the synergistic activation of target gene 
transcription [21].
After CARM1 methylation modifies p300, the interaction between SRC and p300 
is inhibited [6]. CARM1 also methylates SRC-3 and destabilizes the SRC-3/CARM1 
complex [22] (Figure 1c). Thus, the assembly of the core ER coactivator complex 
(ERE/ERα/SRC-3a/SRC-3b/p300) is destroyed, and the effect of the ER pathway is 
blocked.
4. Discussion
As a histone acetyltransferase, p300/CBP participate in various carcinogenic signal 
transduction pathways through its acetylation function. Methylated p300/CBP may 
selectively block the transcriptional activation of cAMP-PKA and steroid-dependent 
pathways [23], but after CARM1 methylation modifies p300/CBP, the transmission of 
signaling pathways is blocked in cancer, which seems to be conducive to the suppres-
sion of the transfer of signaling and the expression of signaling pathway components, 
such those in the ER pathway. The methylation of p300/CBP induced by inhibiting the 
interaction between SRC and p300 blocks the formation of the ERE/ERα/SRC-3/p300 
core complex, resulting in the inhibition of cell proliferation and cell growth. In the 
p53-p21 pathway, p21 recruitment by p53 is mediated by p300/CBP that has been mod-
ified by CARM1 methylation, which results in cell cycle blockade and DNA repair. In 
the cAMP-PKA pathway, methylated p300/CBP blocks the activation of CREB, which 
in turn blocks the function of CREB and inhibits cell proliferation and migration. 
Moreover, we speculate that the high expression of p300/CBP in lung cancer tissue 
may be the result of CARM1 methylation of p300/CBP, mediating the activation of 
cancer suppression-related signaling pathways and blocking cancer-related signaling 
pathways. However, the high expression of CARM1 can promote CCNE2 activation 
and accelerate the progression of lung cancer through the methylation of histones. 
Therefore, inhibiting the histone methylation of CARM1 and increasing the methyla-
tion of p300/CBP are new ideas for novel targets and the treatment of lung cancer.
5. Conclusion
CARM1 may promote the apoptosis of cancer cells and inhibit the metas-
tasis of cancer cells through the methylation of p300/CBP. The mechanism for 
inhibiting the occurrence of lung cancer may involve blocking the activation of 
oncogenic signaling pathways and mediating the activation of tumor suppressor 
signaling pathways.
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